Cefadroxil

Compare Cefadroxil  to:
Compare
Compare

Generic Name for Cefadroxil

Cefadroxil 500mg; caps.

Legal Classification:

Rx

Pharmacological Class for Cefadroxil

Cephalosporin.

Manufacturer of Cefadroxil

Various generic manufacturers

Indications for Cefadroxil

Susceptible urinary tract, skin and skin structure infections, pharyngitis/tonsillitis, impetigo.

Adult dose for Cefadroxil

Uncomplicated UTI: 1–2g once daily or in 2 divided doses. Complicated UTI: 2g/day in 2 divided doses. Skin and skin structure infections: 1g once daily or in 2 divided doses. Pharyngitis/tonsillitis: 1g once daily or in 2 divided doses for 10 days. Renal dysfunction (CrCl <50mL/min): 1g loading dose, then 500mg at increased dosing intervals (see literature). Continue for 3 days after symptoms improve.

Children's dosing for Cefadroxil

UTI, skin and skin structure infections: 30mg/kg/day in 2 divided doses every 12 hours. Pharyngitis/tonsillitis, impetigo: 30mg/kg once daily or in 2 divided doses for 10 days. Renal dysfunction: reduce dose (see literature). Continue for 3 days after symptoms improve.

Also:

Precautions for Cefadroxil

Penicillin or other allergy. Discontinue if colitis occurs and treat. Impaired renal function (CrCl <50mL/min). GI disease (esp. colitis). Pregnancy (Cat.B). Nursing mothers.

Interactions for Cefadroxil

Potentiated by probenecid. May cause false (+) Clinitest or Coomb's test.

Adverse Reactions for Cefadroxil

GI upset, anaphylaxis, rash; blood dyscrasias (rare).

How is Cefadroxil supplied?

Contact supplier.

Related Disease:

Infections, bacterial~systemic antiinfectives

Related Resources

Cayston inhaled antibiotic approved for cystic fibrosis

February 23, 2010

The FDA has approved Cayston (aztreonam for inhalation solution, from Gilead Sciences) as a treatment to improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa.

Phase 3 study of fidaxomicin for clostridium difficile infection (CDI)

February 05, 2010

Optimer Pharmaceuticals announced positive top-line results from the second of two Phase 3 trials evaluating the safety and efficacy of fidaxomicin (OPT-80) in patients with Clostridium difficile Infection (CDI).

Exel/Exelint infusion set needles recalled

January 26, 2010

FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets, and Exel/Exelint "Securetouch+" Safety Huber Infusion Sets due to 'coring,' the cutting or dislodging of silicone cores or slivers from the ports into which they are inserted).

Phase 2 study of Arikace for treatment of pseudomonas lung infections

October 19, 2009

Transave reported additional positive clinical trial results on its lead investigational drug, Arikace (liposomal amikacin for inhalation), an antibiotic to treat chronic lung infections.

Vibativ approved for complicated skin and skin structure infections

September 18, 2009

The FDA has approved Vibativ (telavancin, from Theravance and Astellas), a bactericidal, once-daily injectable lipoglycopeptide antibiotic.